120 related articles for article (PubMed ID: 7982210)
1. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.
Finnegan MC; Goepel JR; Royds J; Hancock BW; Goyns MH
Cancer Lett; 1994 Nov; 86(2):215-21. PubMed ID: 7982210
[TBL] [Abstract][Full Text] [Related]
2. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression.
Martinez JC; Mateo M; Sánchez-Beato M; Villuendas R; Orradre JL; Algara P; Sánchez-Verde L; García P; López C; Martínez P
J Pathol; 1995 Sep; 177(1):27-34. PubMed ID: 7472776
[TBL] [Abstract][Full Text] [Related]
3. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
4. mdm-2 oncogene expression in non-Hodgkin's lymphomas.
Kawamata N; Miller C; Levy V; Shintaku IP; Koeffler HP; Said JW
Diagn Mol Pathol; 1996 Mar; 5(1):33-8. PubMed ID: 8919543
[TBL] [Abstract][Full Text] [Related]
5. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
6. P53 protein expression in lymphomas and reactive lymphoid tissue.
Villuendas R; Piris MA; Orradre JL; Mollejo M; Algara P; Sanchez L; Martinez JC; Martinez P
J Pathol; 1992 Mar; 166(3):235-41. PubMed ID: 1381424
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
9. p53 expression in lymphatic malignancies.
Soini Y; Pääkkö P; Alavaikko M; Vähäkangas K
J Clin Pathol; 1992 Nov; 45(11):1011-4. PubMed ID: 1452775
[TBL] [Abstract][Full Text] [Related]
10. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
11. High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53.
Soini Y; Raunio H; Pääkkö P
Tumour Biol; 1998; 19(3):176-85. PubMed ID: 9591044
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virus.
Tzardi M; Kouvidou C; Panayiotides I; Koutsoubi K; Stefanaki K; Giannikaki E; Darivianaki K; Zois M; Eliopoulos G; Kakolyris S; Delides G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(5A):2813-9. PubMed ID: 8917390
[TBL] [Abstract][Full Text] [Related]
13. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
14. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
15. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
16. MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.
Finnegan MC; Royds J; Goepel JR; Lorigan P; Hancock BW; Goyns MH
Leuk Lymphoma; 1995 Jul; 18(3-4):297-302. PubMed ID: 8535196
[TBL] [Abstract][Full Text] [Related]
17. Increased mdm-2 expression in a p53-independent manner blocks UV-induced cell cycle arrest and apoptosis in human osteosarcoma cells.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Tumour Biol; 2003; 24(3):130-9. PubMed ID: 14610316
[TBL] [Abstract][Full Text] [Related]
18. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma.
Moch H; Sauter G; Gasser TC; Buchholz N; Bubendorf L; Richter J; Jiang F; Dellas A; Mihatsch MJ
Urol Res; 1997; 25 Suppl 1():S25-30. PubMed ID: 9079753
[TBL] [Abstract][Full Text] [Related]
19. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin's lymphomas.
Lee KA; Finnegan MC; Sheridan E; Hancock BW; Goepel JR; Royds J; Goyns MH
Ann Oncol; 1994; 5 Suppl 1():85-8. PubMed ID: 8172825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
